Phanes Therapeutics Revenue and Competitors

Phanes Therapeutics, Inc. is a biotech company focused on innovative drug discovery and early development in immuno-oncology and eye disease. Our mission is to become a major source of innovation in the biopharma industry. The way we focus on science, the disruptive technologies we develop, and the revolutionary approaches we bring help open up new possibilities in drug discovery. At Phanes, we bring innovation that illuminates the path to cure. Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. One of our therapeutic approaches is to boost both the innate and adaptive immunity with monoclonal antibodies and bispecific antibodies. We are also interrogating non-immune pathways that may play key roles in the tumor microenvironment for their potential in developing novel therapeutics. In addition to a strong pipeline, Phanes has developed disruptive technologies that enable drug discovery. Phanes' three novel technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties. The company has three technology platforms: PACbody™ (for building native IgG-like bispecific antibodies), ATACCbody™ (for building bispecific antibodies with modulated activities) and SPECpair™ (for building bispecific antibodies with enhanced manufacturability). For more information, please visit www.phanesthera.com